<dd id='5bcYb'><tbody id='5IvhP'><td id='covNY'><optgroup id='dKWTu'><strong id='59xBx'></strong></optgroup><address id='vRTB3'><ul id='68ddy'></ul></address><big id='pagpv'></big></td><table id='K5pBB'></table></tbody><pre id='RAuGx'></pre></dd><span id='4SAyT'><b id='7OLAQ'></b></span>
<dfn id='KOaiv'><optgroup id='WahnO'></optgroup></dfn><tfoot id='8Kfi6'><bdo id='GvNwj'><div id='Ni77h'></div><i id='faf8o'><dt id='GbkEc'></dt></i></bdo></tfoot>
<ul id='2ddgT'></ul>
<fieldset id='0VRJF'></fieldset>
百(bai)奧賽圖(tu)(北(bei)京)醫(yi)(yi)藥科技(ji)股份有限公(gong)司宣(xuan)布其自(zi)主研發的全球首創雙特異(yi)性抗體YH008(PD-1 x CD40)的IND申請獲(huo)得美國FDA批準。此次IND申報由百(bai)奧賽圖(tu)全資子(zi)公(gong)司祐和醫(yi)(yi)藥完成。（醫(yi)(yi)藥健(jian)聞(wen)）
<option id='o827b'></option><select id='NauiM'><span id='ROGNW'><form id='TraYn'></form></span><dd id='uYL7e'></dd></select><dt id='O0dI5'></dt><style id='O7Wod'><big id='RdcPk'><i id='FDK8H'></i><tbody id='UOQ4E'></tbody></big></style><abbr id='ONawD'></abbr>
